Brokerages expect Nektar Therapeutics (NASDAQ:NKTR) to report earnings of ($0.80) per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings. The highest EPS estimate is ($0.75) and the lowest is ($0.86). Nektar Therapeutics posted earnings of $5.33 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 115%. The firm is scheduled to report its next earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($3.14) per share for the current year, with EPS estimates ranging from ($3.30) to ($3.00). For the next fiscal year, analysts forecast that the company will post earnings of ($2.91) per share, with EPS estimates ranging from ($3.92) to ($2.21). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The company had revenue of $28.22 million during the quarter, compared to analyst estimates of $25.45 million. During the same quarter in the previous year, the firm posted ($0.60) EPS.
NKTR stock traded down $1.33 during trading on Wednesday, reaching $33.29. 1,158,299 shares of the company’s stock were exchanged, compared to its average volume of 1,681,339. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21. Nektar Therapeutics has a 1-year low of $29.22 and a 1-year high of $69.76. The company has a fifty day simple moving average of $33.40. The stock has a market capitalization of $5.91 billion, a price-to-earnings ratio of 8.81 and a beta of 2.82.
In other news, CFO Gil M. Labrucherie sold 25,000 shares of the business’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $33.71, for a total value of $842,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Howard W. Robin sold 100,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $33.00, for a total value of $3,300,000.00. Following the sale, the chief executive officer now directly owns 328,659 shares in the company, valued at $10,845,747. The disclosure for this sale can be found here. Insiders sold a total of 184,949 shares of company stock worth $6,075,350 in the last three months. Company insiders own 4.02% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in shares of Nektar Therapeutics by 8.5% during the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock worth $853,355,000 after purchasing an additional 2,041,954 shares during the period. Vanguard Group Inc boosted its stake in shares of Nektar Therapeutics by 3.6% during the 3rd quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock worth $1,153,525,000 after acquiring an additional 660,907 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Nektar Therapeutics by 11.6% during the 4th quarter. First Trust Advisors LP now owns 2,309,172 shares of the biopharmaceutical company’s stock worth $75,902,000 after acquiring an additional 240,272 shares in the last quarter. Norges Bank bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth about $63,723,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Nektar Therapeutics by 1.3% during the 4th quarter. Bank of New York Mellon Corp now owns 1,418,699 shares of the biopharmaceutical company’s stock worth $46,634,000 after acquiring an additional 17,670 shares in the last quarter. 92.23% of the stock is currently owned by institutional investors.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Further Reading: Why investors pay attention to retained earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.